Axsome Therapeutics, Inc. (AXSM) Investor Relations Documents

Axsome Therapeutics, Inc. (AXSM) investor relations documents from the company's IR site: 2 presentations, 21 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.

Second Quarter 2026 Corporate Presentation: Axsome Therapeutics reported 2Q 2026 total product revenue of $218.4 million, a 46% increase year-over-year, driven by AUVELITY and SUNOSI commercial growth.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10PresentationSecond Quarter 2026 Corporate Presentation
2026-08-10Press releaseAxsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-15Press releaseAxsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcol
2026-07-14Press releaseAxsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
2026-07-07Press releaseAxsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Dis
2026-06-26Press releaseAxsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity
2026-06-18Press releaseAxsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
2026-06-15Press releaseAxsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
2026-06-04Press releaseAxsome Therapeutics Presents New SYMBRAVO® Data at the American Headache Society (AHS) 68th Annual Scientific Meeting
2026-06-03Press releaseAxsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
2026-06-01Press releaseAxsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache
2026-05-26Press releaseAxsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychop
2026-05-07Press releaseAxsome Therapeutics Recognizes Mental Health Month
2026-05-05Press releaseAxsome Therapeutics to Participate in Upcoming Investor Conferences
2026-05-01PresentationAUVELITY in Agitation Associated with Dementia due to Alzheimer’s Disease FDA Approval Call Presentation
2026-05-01Press releaseAxsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
2026-04-30Press releaseAxsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Ag
2026-04-01Press releaseAxsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsy
2026-02-25Press releaseAxsome Therapeutics to Participate in Upcoming Investor Conferences
2026-02-24Press releaseAxsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excess
2026-02-18Press releaseAxsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-01-15Press releaseAxsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
2026-01-12Press releaseAxsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

AXSM overview · AXSM earnings · AXSM financials · AXSM KPIs · AXSM documents · AXSM ownership · AXSM peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.